Pharmaceuticals from United Kingdom: 10% US Tariff (2026)

Importing pharmaceuticals from United Kingdom into the United States carries an effective tariff of about 10% in 2026. That breaks down as 10% Base tariff — the product's MFN base duty plus the 10% Section 301 forced-labor tariff that replaced the expired Section 122 rate on July 24, 2026.

United Kingdom sits in the 10% tier of the Section 301 forced-labor tariff that replaced the expired Section 122 rate on July 24, 2026, layered on the product's MFN base. It is not subject to the China-specific Section 301 duties, which keeps pharmaceuticals from United Kingdom well below Chinese-origin equivalents.

Pharmaceuticals imports fall under HTS chapters 30. On a $10,000 shipment, the ~10% effective rate works out to roughly $1,000 in duty before the Merchandise Processing Fee (0.3464%) and, on ocean freight, the Harbor Maintenance Fee (0.125%). Because the exact duty depends on the specific HTS code and materials, confirm the classification with the HTS Code Finder and run your country and declared value through the tariff calculator on this page for the fully stacked number.

Refund angle: if you imported pharmaceuticals from United Kingdom between April 2025 and February 2026, you likely paid the IEEPA reciprocal tariff (about 10%) that the Supreme Court struck down on February 20, 2026 in Learning Resources v. Trump. That layer is now recoverable from the roughly $166 billion CBP refund pool through the CAPE reliquidation process, plus statutory interest near 5%. Section 301 and Section 232 duties were not struck down and are not refundable. The Phase 1 window covers unliquidated entries and those within 80 days of liquidation.

Bottom line for pharmaceuticals importers sourcing from United Kingdom: confirm the HTS classification, budget for the 10% stacked rate, and — if you paid IEEPA duties in 2025 — check refund eligibility before Phase 1 windows close on a rolling basis.